Go to about.hse.ie for information about the HSE as an organisation, the health regions, News and Publications.


The calcitonin gene-related peptide (CGRP) monoclonal antibodies (MABs) erenumab (Aimovig®), fremanezumab (Ajovy®) and galcanezumab (Emgality®) are available under the High Tech Arrangement and eptinezumab (Vyepti®) is available under hospital pricing approval. A Managed Access Protocol is in place for the CGRP MABs. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of erenumab, fremanezumab or galcanezumab under the High Tech Arrangement, or eptinezumab under hospital pricing approval.

The prescribing of erenumab (Aimovig®), fremanezumab (Ajovy®) and galcanezumab (Emgality®) under the High Tech Arrangement and eptinezumab (Vyepti®) under hospital pricing approval is confined to consultant neurologists who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme.

The clinician must submit an online application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

A copy of the HSE-Managed Access Protocol for CGRP MABs can be found in the Related Files section below.

The HSE have approved 42 prescribers for CGRP MABs under this protocol to date. By April 2023, over 1,000 patients were accessing treatment with a CGRP MAB each month under the High Tech Arrangement.

Update on Calcitonin Gene-Related Peptide Monoclonal Antibodies (PDF, 617 KB, 1 page)